Novartis, CH0012005267

Novartis wins Rhapsido approval as Bank of America keeps CHF 150 target for Novartis stock

Published on 10/16/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis receives FDA approval for Rhapsido on October 7, 2026. Novartis stock costs EUR 134.39 on October 16, 2026 at Lang & Schwarz.

Rhapsido approval and upcoming dates

Rhapsido received FDA approval for symptomatic dermographism on October 7, 2026.
Second-quarter revenue reached CHF 14.16 billion on June 30, 2026, versus CHF 14.84 billion a year earlier.
Novartis stock trades at EUR 134.39 at 10:39 a.m. CEST at Lang & Schwarz on October 16, 2026.

Börsenanzeigetafel mit Candlestick-Charts und Händlern auf einem Schweizer Handelsparkett — Novartis AG CH0012005267 – Börsentafel mit Pharmacharts und Händlern auf belebtem Schweizer Trading-Floor, Illustration mit AI erstellt.

Novartis received FDA approval for Rhapsido on October 7, 2026, expanding the medicine's use to symptomatic dermographism. The approval adds a new commercial application as the pharmaceutical group prepares its next quarterly update, according to Novartis.

Rhapsido expands the launch base

The FDA decision gives remibrutinib, marketed as Rhapsido, an additional indication beyond chronic spontaneous urticaria. Novartis listed the approval among its October 7, 2026 press releases, while also highlighting multiple sclerosis data for its broader portfolio.

The commercial opportunity arrives alongside a mixed recent earnings comparison. For the quarter ended June 30, 2026, Novartis reported revenue of CHF 14.16 billion and net profit of CHF 3.21 billion, compared with CHF 14.84 billion and CHF 4.04 billion in the same period a year earlier, according to Markets Insider.

What do analysts expect next?

Bank of America Securities kept a Buy rating and a CHF 150.00 target for Novartis in an October 12, 2026 note, citing the pipeline and the ability of newer products to offset patent pressure, according to TipRanks. Barclays separately maintained a Hold rating with a CHF 130.00 target on October 13, 2026.

Two dates define the next phase

Novartis is scheduled to host a Remibrutinib in MS investor call on October 23, 2026. The company has scheduled its third-quarter results for October 27, 2026, with the webcast listed on its investor calendar.

Price stays tied to the next update

Novartis stock was trading at EUR 134.39 at Lang & Schwarz on October 16, 2026, at 10:39 a.m. CEST. The next results date gives investors a concrete checkpoint for assessing whether the new indication and the wider pipeline can support growth.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.